Medical treatment of diabetic foot infections

被引:273
作者
Lipsky, BA
机构
[1] VA Puget Sound Hlth Care Syst, Gen Internal Med Clin, Seattle, WA 98108 USA
[2] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA
关键词
D O I
10.1086/383271
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Diabetic foot infections frequently cause morbidity, hospitalization, and amputations. Gram-positive cocci, especially staphylococci and also streptococci, are the predominant pathogens. Chronic or previously treated wounds often yield several microbes on culture, including gram-negative bacilli and anaerobes. Optimal culture specimens are wound tissue taken after debridement. Infection of a wound is defined clinically by the presence of purulent discharge or inflammation; systemic signs and symptoms are often lacking. Only infected wounds require antibiotic therapy, and the agents, route, and duration are predicated on the severity of infection. Mild to moderate infections can usually be treated in the outpatient setting with oral agents; severe infections require hospitalization and parenteral therapy. Empirical therapy must cover gram-positive cocci and should be broad spectrum for severe infections. Definitive therapy depends on culture results and the clinical response. Bone infection is particularly difficult to treat and often requires surgery. Several adjuvant agents may be beneficial in some cases.
引用
收藏
页码:S104 / S114
页数:11
相关论文
共 89 条
[31]  
FOSTER AVM, 1998, 3 INT S DIAB FOOT NO
[32]  
Frykberg RG, 2000, WOUNDS SB, V12, p35B
[33]  
GER R, 1984, SURG GYNECOL OBSTET, V158, P213
[34]   FOOT INFECTIONS IN DIABETIC-PATIENTS - THE ROLE OF ANAEROBES [J].
GERDING, DN .
CLINICAL INFECTIOUS DISEASES, 1995, 20 :S283-S288
[35]   Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection [J].
Gough, A ;
Clapperton, M ;
Rolando, N ;
Foster, AVM ;
PhilpottHoward, J ;
Edmonds, ME .
LANCET, 1997, 350 (9081) :855-859
[36]   Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: A randomized, open-label trial [J].
Graham, DR ;
Talan, DA ;
Nichols, RL ;
Lucasti, C ;
Corrado, M ;
Morgan, N ;
Fowler, CL .
CLINICAL INFECTIOUS DISEASES, 2002, 35 (04) :381-389
[37]   USE OF AMPICILLIN/SULBACTAM VERSUS IMIPENEM/CILASTATIN IN THE TREATMENT OF LIMB-THREATENING FOOT INFECTIONS IN DIABETIC-PATIENTS [J].
GRAYSON, ML ;
GIBBONS, GW ;
HABERSHAW, GM ;
FREEMAN, DV ;
POMPOSELLI, FB ;
ROSENBLUM, BI ;
LEVIN, E ;
KARCHMER, AW .
CLINICAL INFECTIOUS DISEASES, 1994, 18 (05) :683-693
[38]   PROBING TO BONE IN INFECTED PEDAL ULCERS - A CLINICAL SIGN OF UNDERLYING OSTEOMYELITIS IN DIABETIC-PATIENTS [J].
GRAYSON, ML ;
GIBBONS, GW ;
BALOGH, K ;
LEVIN, E ;
KARCHMER, AW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (09) :721-723
[39]   Use of sulesomab, a radiolabeled antibody fragment, to detect osteomyelitis in diabetic patients with foot ulcers by lenkoscintigraphy [J].
Harwood, SJ ;
Valdivia, S ;
Hung, GL ;
Quenzer, RW .
CLINICAL INFECTIOUS DISEASES, 1999, 28 (06) :1200-1205
[40]   BACTERIAL-FLORA IN MAL PERFORANT AND ANTIMICROBIAL TREATMENT WITH CEFTRIAXONE [J].
HIRSCHL, M ;
HIRSCHL, AM .
CHEMOTHERAPY, 1992, 38 (04) :275-280